NewAmsterdam Pharma Co N.V.

NAMS

Explore Our Financial Data > Companies > NewAmsterdam Pharma Co N.V.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
NAMS
CIK0001936258
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

AddressGOOIMEER 2-35, NARRDEN, P7, 1411 DC
Website newamsterdampharma.com
Phone35 206 2971
CEOMichael H. Davidson
Employees4

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$47.14 million
Pre-Tax Income$-187.36 million
Net Income$-187.36 million
Net Income to Common$-187.36 million
EPS$-1.84
View All
Balance Sheet
Cash$748.42 million
Assets$818.41 million
Liabilities$41.05 million
Common Equity$777.36 million
Liabilities & Equity$818.41 million
View All
Cash Flow Statement
Net Income$-187.36 million
Cash From Operating Activities$-140.43 million
Cash From Investing Activities$-59.61 million
Cash From Financing Activities$467.85 million
Change in Cash$267.81 million
View All
Calculations
NOPAT$-132.81 million
EBITDA$-209.10 million
Price to EarningsN/A
Price to Book$2.79
ROE-31.51%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

NAARDEN, The Netherlands and MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAm

Article Link

NewAmsterdam Pharma First Quarter 2025 Earnings: US$0.34 loss per share (vs US$1.06 loss in 1Q 2024)

NewAmsterdam Pharma ( NASDAQ:NAMS ) First Quarter 2025 Results Key Financial Results Revenue: US$2.98m (up 113% from 1Q...

Article Link

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively -- -- Company to host R&D day on June 11th, 2025 in New York City -- –$808.5 million in cash, cash equivalents and marketable securities at March 31, 2025 – NAARDEN, The Netherlands and MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N

Article Link

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – Phase 3 data showed that obicetrapib as an adjunct to statins, whether in combination with ezetimibe or as monotherapy, reduced LDL-C by 50% and 35%, respectively; in addition, Phase 2 data of obicetrapib in combination with moderate-dose statins showed LDL-C reductions of approximately 70% – – 21% observed reduction in major ad

Article Link

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s

Article Link